6 results
* Part A: To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of increasing doses of YTX-7739 in healthy subjects. * Part B: To study the effect of food on pharmacokinetics of YTX-7739 in a selection of subjects who…
This study is designed to assess the efficacy of pralsetinib as compared to Investigator*s choice platinum-based chemotherapy regimen for patients with metastatic NSCLC harboring an oncogenic RET fusion and who have not received prior systemic…
This study is designed to assess the efficacy of pralsetinib as compared to Investigator*s choice platinum-based chemotherapy regimen for patients with metastatic NSCLC harboring an oncogenic RET fusion and who have not received prior systemic…
The primary objective of this study is to assess the pharmacokinetics and the effect of food on the pharmacokinetics of the YTX-7739 tablet formulation following single oral doses of 30 mg in HVs and to compare the relative bioavailability of the…
To investigate the safety, tolerability and pharmacokinetics after multiple daily doses of YTX-7739
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…